TELA
What one share of TELA Bio holds
Surgical and Medical Instruments and Apparatus
We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy.
TELA Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.51 |
|---|---|
| Profit | −$0.78 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.60 |
| Cash and investments | $0.68 |
| Debt | $1.25 |
| Book value | −$0.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $14.54 | −$93.25 | $0.39 | −$56.45 | — | −$370.50 |
| 2018 | $28.05 | −$101.41 | $0.21 | −$67.75 | — | −$466.19 |
| 2019 | $8.74 | −$17.10 | $0.11 | −$14.56 | — | — |
| 2020 | $1.41 | −$2.23 | $0.01 | −$1.90 | — | $3.40 |
| 2021 | $2.04 | −$2.30 | $0.04 | −$2.15 | — | $1.38 |
| 2022 | $2.55 | −$2.72 | $0.05 | −$2.56 | — | $0.75 |
| 2023 | $2.56 | −$2.04 | $0.03 | −$1.81 | — | $0.77 |
| 2024 | $2.43 | −$1.33 | $0.03 | −$1.49 | — | $0.72 |
| 2025 | $1.71 | −$0.83 | $0.01 | −$0.61 | — | $0.14 |